EGFR positive

Low rates of loco-regional recurrence were observed in this retrospective cohort of breast cancer patients with SLN micrometastases, who underwent mastectomy without ALND or PMRT.

The patient was treated with tamoxifen and adjuvant chest wall + axillary radiotherapy. At follow-up, he remains disease-free with a good quality of life. This case highlights the importance of early suspicion in male breast lesions and emphasizes individualized management integrating tumor biology, stage, and patient factors.

In this retrospective case series study, all patients with EGFR-mutated NSCLC who developed fatal pneumonitis during first-line osimertinib monotherapy had a history of heavy smoking. These findings suggest that patients with a substantial smoking history may require closer monitoring to reduce the risk of Grade 5 pneumonitis.

Despite a decrease in CT declination over time, disparities persist, and declination is associated with worse OS. Further research is needed to understand these disparities and improve cancer care delivery and outcomes.

P2, N=6, Terminated, OHSU Knight Cancer Institute | N=30 --> 6 | Trial completion date: Jun 2033 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Mar 2026; Loss of support.

Consensus was defined a priori as ≥75% agreement. This 2025 update incorporates new data in early-stage, metastatic, and central nervous system-involved disease, including revisions to neoadjuvant and adjuvant treatment pathways and expanded guidance on the clinical use of antibody-drug conjugates.

Recently, the oral, selective AKT kinase inhibitor capivasertib has been approved for the treatment of estrogen receptor-positive/human HER2-growth factor receptor-2 advanced BC with alterations in PIK3CA/AKT1/PTEN, in combination with fulvestrant after progression on endocrine therapy. We performed a narrative review to recapitulate the available evidence about capivasertib in the management of advanced hormone receptor-positive, HER2-negative breast cancer, focusing on studies that address preclinical rationale, pharmacology, and clinically relevant problems.

Hematologic adverse events are well characterized with the three currently approved CDK4/6 inhibitors, namely palbociclib, abemaciclib, and ribociclib. Among non-hematologic toxicities, there is a paucity of information regarding cutaneous adverse events related to these three medications. In this case report, we seek to describe the incidence, time to onset, and management of CDK4/6-mediated cutaneous adverse events.

Pathologic processing met established fixation standards.This case highlights the importance of histologic subtype and proliferative activity in guiding risk stratification and management considerations for breast cancer in elderly patients. Recognition of indolent tumor biology may help avoid overtreatment while maintaining oncologic safety.

In vivo studies demonstrated pronounced tumor growth inhibition by A9-DA1 in HER2+ xenograft and P6-DA1 in EGFR+ KRAS mutated colorectal and pancreatic xenograft models. Overall, our findings suggest that Ahx-DA1 is a highly effective auristatin-class payload for the development of DA1 based anticancer PDCs.

P2, N=38, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences